Clinical Trial Update: Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adding aprepitant to multimodal prophylaxis for postoperative nausea and vomiting in high-risk outpatient surgical patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Nausea and Vomiting

Drugs mentioned

• Aprepitant (aprepitant)

Snippet

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) | Conditions: Nausea and Vomiting, Postoperative, Prevention | Phase 3 | Status: COMPLETED